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CALIFORNIA PENAL CODE SECTION 645:
LEGISLATORS PRACTICE MEDICINE
ON CHILD MOLESTERS
On September 17, 1996, California Governor Pete Wilson signed into
law the nation's first statute mandating chemical castration' for certain
recidivist sex offenders.2 The law authorizes courts to impose medroxy-
progesterone acetate (MPA) treatment upon parole of first time offend-
ers of specified sex offenses and requires MPA treatment upon parole of
second time offenders where the victim is under the age of thirteen.
3
Assemblyman Bill Hoge, the author of the bill, said at the signing cere-
mony, "We have now set the stage for America .... We can do this all
over the country. This is going to have the biggest impact on this horri-
ble, horrible crime of any 'legislation ever seen."4
In the past several years, California actively pursued legislative reme-
dies to combat the troubling problem of recidivism of convicted sex of-
fenders. The first of such remedies was the Sexually Violent Predators
Act, permitting the Departments of Corrections or Mental Health to rec-
ommend civil commitment for particularly violent sex offenders. 5 The
1. The term "chemical castration" is something of a misnomer. Unlike surgi-
cal castration, it does not involve a mutilation of the body, and is not permanent.
See Linda S. Grossman, Research Directions in the Evaluation and Treatment of
Sex Offenders, 3 BEHAV. Sc. & L. 421, 426 (1985). The term refers to the use of
antiandrogens, which are synthetic hormones that decrease the body's production
of testosterone, for the treatment of certain sexual disorders. See id The treatment
specified in the statute is discussed in some detail in this Comment. See infra Part
I(B) and Part III(A).
Throughout this Comment, the terms "chemical castration" and "MPA treat-
ment" have the same meaning. Generally, "chemical castration" is used in the
sections of the Comment concerning the legislation, while "MPA treatment" is
used in the section describing the medical aspects. The term "chemical castration,"
rather than the neutral "MPA treatment," is used intentionally to emphasize the
profound effect that this medication has on the body.
2. See CAL. PENAL CODE § 645 (West Supp. 1997), 1996 Cal. Stats. 596 § 2
(A.B. 3339).
3. See id § 645.
4. Dave Lesher, Molester Castration Measure Signed, L.A. TIMES, Sept. 18,
1996, at A3.
5. See CAL. WELF. & INST. CODE §§ 6600-6609.3. (West 1998). "Of 747
recommendations made so far ... only two commitments have been made after
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Registration Act,6 a community notification and registration law mod-
eled after Megan's Law was then enacted.7 The chemical castration law
followed.'
While California is the first state to enact a chemical castration law, it
is not alone. Three other states, Georgia, 9 Montana,'0 and Louisiana"
have since enacted similar legislation, while a number of other states
jury trials." Katherine Seligman, Chemical Castration Costly, Will It Work, S.F.
EXAMINER, Sept. 15, 1996, at C 1.
6. See 1994 CAL. STAT. 894 (A.B. 3513).
7. See CAL. PENAL CODE § 290 (registration), § 290.4 (community notifica-
tion) (West Supp. 1999).
8. See id. § 645. Another bill, requiring released child sex offenders to
wear an identification bracelet, was also introduced, but not enacted. See A.B.
614, Reg. Sess. (Cal 1997). This bill would have required convicted child mo-
lesters to wear a two-inch wide metal bracelet, which would be engraved with
the victim's name and age if the victim's family consented. See id. Unauthor-
ized removal of the bracelet would send the molester back to prison for the
remainder of his parole period. See id. Like the chemical castration bill, this
bill was sponsored by the Women's Coalition. See Dan Bernstein, Plan for
Molester ID Bracelet Advances, Sacramento Bee, Apr. 23, 1997, at A5.
9. See GA. CODE ANN. § 16-6-4(d)(2) (Supp. 1998). This section authorizes
the court to require a person convicted of a first offense of aggravated child moles-
tation to undergo psychiatric evaluation to determine if medroxyprogesterone ace-
tate treatment would be an effective treatment, and if so, to require such treatment
as a condition of probation. Section § 42-9-44.2 authorizes the Board of Pardons
and Paroles to require counseling, at the parolee's expense, and medroxyprogester-
one acetate treatment as a condition of parole of a person convicted of a second or
subsequent offense of child molestation. See id. § 42-9-44.2.
10. See MONT. CODE ANN. § 45-5-512 (1997). Montana's statute, like Cali-
fornia's, requires medroxyprogesterone acetate treatment following second convic-
tion of an offense of certain enumerated sex offenses. See id. § 2. The treatment
begins one week prior to release from confinement and continues "until the de-
partment of corrections determines that the treatment is no longer necessary." Id.
§4.
I1. See LA. REv. STAT. ANN. § 15:538(C) (West Supp. 1999). This statute
authorizes MPA treatment as a condition of probation, parole, or suspended sen-
tence for certain sex offenses, including first convictions where the victim is under
the age of twelve, and second or subsequent convictions of specified offenses. See
id The law requires that the treatment continue for the duration of the term of
probation, parole, or suspended sentence, unless it is determined that the treatment
is no longer necessary. See id. The offender pays the cost of the treatment under
this statute. See id.
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have recently considered chemical castration measures. 2 All of these
measures contemplate statutes that either require or permit MPA treat-
ment.
California's concern about the prevalence of sexual violence in the
United States today is not misplaced.13 One study estimated that twenty
percent of all females and ten percent of all males were molested before
the age of eighteen. 14 The public solution to preventing sexual offenses
12. These states include Alabama, H.B. 8 (Ala. 1997) (requiring chemical cas-
tration for second time sex offenses against children under the age of 13); Arizona,
H.B. 2216, 43d Leg., 1st Reg. Sess. (Ariz. 1997); Colorado, H.B. 1133, 61st G.A.,
1st Reg. Sess. (Colo. 1997) (requiring chemical castration of second convictions of
sex offenses against children); Hawaii, S.B. 215, 19th Leg. (Haw. 1997) (permit-
ting person convicted of second sex offense where the victim is under the age of 14
to be punished by medroxyprogesterone acetate treatment); Michigan, H.B. 4796,
89th Leg., 1997 Reg. Sess. (Mich. 1997) (requiring chemical castration of sex of-
fenders as a condition of parole); Mississippi, S.B. 2042, 2465, 1997 Reg. Sess.
(Miss. 1997) (requiring chemical castration for second conviction of rape and for a
second sex offense); Missouri, H.B. 753, 89th G.A., 1st Reg. Sess. (Mo. 1997)
(making MPA treatment a sentencing option for ceitain sexual offenders); New
Jersey, S.B. 1568, 207th Leg., 1st Sess. (N.J. 1997) (requiring chemical castration
of certain sex offenders); Oregon, H.B. 3672, 69th Leg., 1997 Reg. Sess. (Or.
1997) (permitting parole board to require a person to undergo chemical castration
as a condition of post-prison supervision); Tennessee, H.B. 482, 483, 585, 100th
G.A. (Tenn. 1997) (authorizing judges to impose chemical castration as condition
of community supervision for life; mandating chemical castration of second con-
viction of sex offense where the victim is less than 13 years of age; permitting
chemical castration treatment for second conviction of aggravated sexual battery
against a child; requiring judges to impose chemical castration as a condition of
community supervision for life of certain sex offenders); S.B. 1152, 1153, 100th
G.A. (Tenn. 1997) (permitting chemical castration upon second conviction of ag-
gravated sexual battery where the victims are children; authorizing'judges to im-
pose chemical castration as a condition of community supervision for life and man-
dating chemical castration for second sexual offense where victim is less than 13
years of age).
13. According to the Bureau of Justice Statistics, in 1991 there were more than
43,000 prisoners nationwide incarcerated for sexual offenses against children. See
Lawrence A. Greenfeld, Child Victimizers: Violent Offenders and their Victims,
Table 1, Bureau of Justice Statistics (1996) (visited Jan. 12, 1999)
<http://www.ojp.usdoj.gov/bjs/pub/pdf/cvvoatv.pdf>. In 1995, California reported
that it had 13,548 incarcerated sex offenders, more than ten percent of the state's
total prisoner population. See DEPARTMENT OF JUSTICE, SOURCEBOOK OF
CRIMINAL JUSTICE STATISTICS 1996 537 (1997).
14. See Gene G. Abel and Candice A. Osborn, Pedophilia, in TREATMENTS OF
19991
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and other acts of violence tends to focus on criminal penalties. 5 Over
the past decade, however, the medical community has been advocating a
more comprehensive approach, stressing that these crimes are also a
public health crisis.
1 6
When properly administered, MPA treatment could be a valuable
contribution from the medical community to respond to this crisis. The
treatment works by reducing the amount of testosterone in the male pa-
tient through an injection of a synthetic progesterone.' 7 The use of MPA
to treat individuals with certain sexual disorders, including pedophilia,
has been studied in the United States since the late 1960s.18 Specialists
have identified MPA treatment as the most promising available treat-
ment for some sex offenders.' 9 Compared to other available psychiatric
treatments, numerous studies indicate that MPA treatment produces the
most favorable success rate in preventing relapse or recidivism. 20 How-
ever, the relapse rate is as high as fifteen percent when an individual is
undergoing MPA treatment and rises considerably after MPA treatment
is discontinued.2'
In requiring sex offenders to receive a medical treatment, California,
PSYCHIATRIC DISORDERS 1960 (Glen 0. Gabbard ed., 1995) (citing a 1986 study).
A 1995 study on adolescent health by the Johns Hopkins School of Medicine re-
ported that 10.5% of children between the ages of 10 and 16 suffered sexual assault
or abuse. See Michele D. Wilson Alain Joffe, Adolescent Medicine, 273 JAMA
1657, 1657 (1995).
15. See James A. Mercy et al., Public Health Policy for Preventing Violence,
12 HEALTH AFF. 7, 16 (1993).
16. See id. at 7. The Center for Disease Control has been approaching violence
as a public health issue for a number of years, and in 1991 formed the National
Center for Injury Prevention and Control. See id; see also Robert E. Freeman-
Longo, The Treatment of Sex Offenders: Reducing Sexual Abuse in America, 23
N.E. J. CRIM. & Civ. CON. 303, 309 (1997). The World Health Assembly and the
American Psychological Association identified violence as a public health crisis.
See id. The American Medical Association called sexual assault the "silent-violent
epidemic" in the United States. See id. at 310 (citing American Medical Associa-
tion, SexualAssault in America, Nov. 6, 1995).
17. See infra Part I(B).
18. See, e.g., John Money, Use of an Androgen-Depleting Hormone in the
Treatment of Male Sex Offenders, 6 J. SEX. RES. 165 (1970).
19. See Linda S. Grossman, Research Directions in the Evaluation and Treat-
ment of Sex Offenders, 3 BEHAV. SC. & L. 421, 435 (1985).
20. See id; see also infra Part I(C) at 7-10.
21. See infra Part I(C) at 8-9.
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at first glance, may appear to be responding to the public health model
of violence prevention. A closer examination of the statute, however,
indicates that California has simply grafted a medical treatment onto the
criminal justice model, adding another type of punishment without rea-
sonable assurance that the treatment will decrease the number of future
sexual assaults. Employing a selective understanding of the available
medical data, California would apply to a broad class of child sex of-
fenders a medical treatment that may only be effective on a subclass of
sexual offenders. 22 By the terms of ihe statute, the legislature has pre-
scribed a continuing medical treatment for a class of offenders without
providing for the traditional role of the doctor: diagnosis, selection of
the appropriate treatment, and monitoring of treatment are left to statu-
tory provisions or are delegated to the California Department of Correc-
21tions. Section 645 is a disturbing legislative usurpation of medicine to
implement criminal justice policy.
This Comment examines California's chemical castration provision
from a public policy perspective. 4 Part One discusses MPA treatment of
sex offenders. This Part is divided into sections. The first section distin-
guishes the criminal conduct of sex offenders from the mental disorder
pedophilia. The second section describes MPA treatment. The third sec-
tion reviews medical research using MPA treatment to treat pedophilia.
Part Two briefly outlines the use of MPA treatment in the criminal jus-
tice system to date. Part Three examines Section 645, its legislative his-
tory, and recent regulation and policy under the statute. Part Four ex-
plores several areas in which the absence of the sound contribution of
the medical profession is most apparent. It looks at the statute's effect of
imposing a "diagnosis" on convicted sex offenders, the troubling ques-
tion of how dosage might be determined, and the uncertain duration of
the treatment. It also discusses some medico-ethical and legal problems
22. See infra Part I(C) at 8.
23. See CAL. PENAL CODE § 645 (West Supp. 1997).
24. The constitutional issues presented by this legislation are beyond the scope
of this Comment. For an Eighth Amendment examination of this statute, see Ray-
mond Lombardo, Note: California's Unconstitutional Punishment for Heinous
Crimes: Chemical Castration of Sexual Offenders, 65 FORDHAM L. REV. 2611
(1997). For constitutional analyses of MPA treatment, see Daniel L. Icenogle,
Sentencing Male Sex Offenders to the Use of Biological Treatments, 15 J. LEGAL
MED. 279 (1994); Pamela K. Hicks, Castration of Sexual Offenders, 14 J. LEGAL
MED. 641 (1993); Edward A. Fitzgerald, Chemical Castration: MPA Treatment of
the Sexual Offender, 18 AM. J. CRiM. L. 1 (1990).
1999]
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with the statute. This Comment concludes by suggesting that, while
MPA treatment could play a valuable role in the prevention of child
sexual abuse, California's provision has the effect of further punishment
rather than competent medical treatment and crime prevention.
I. THE USE OF MPA IN THE TREATMENT OF SEX OFFENDERS
A. Distinguishing Among Sex Offenders
Before discussing the science of MPA treatment or the results of MPA
research, it is necessary to distinguish among various terms. "Sex of-
fender," "child molester," and "pedophile," are terms frequently used
interchangeably. 25 "Pedophile," however, is a medical or psychiatric
term that refers not simply to behavior, but also to particular cognitive
and emotional states. 26 Not all people who commit sexual crimes against
children are pedophiles, although all could be termed sex offenders or
child molesters. 7
A child molester may have one or more causes for his conduct. 28
Some offenses against children are committed by individuals who have
some degree of mental retardation and a consequent inability to appreci-
ate the difference between appropriate and inappropriate sexual behav-
ior.29 An individual with an antisocial personality may commit sexual
offenses against children simply because it is hurtful. 30 A schizophrenic
individual may commit offenses because he has hallucinatory visions or
25. See Gene G. Abel & Joanne L. Rouleau, Sexual Abuses, 18 Psychiatric
Clinics of North America 139, 140-41 (1995).
26. See Fred S. Berlin & Carl F. Meinecke, Treatment of Sex Offenders with
Antiandrogenic Medications, Conceptualization, Review of Treatment Modalities,
and Preliminary Findings, 138 AM. J. PSYCHIATRY 601, 602 (1981).
27. See Abel & Rouleau, supra note 25, at 140. Studies indicate that "between
40% to 50% of the sexual abuse of children is perpetrated by adolescents." Id
(omitting internal citations).
28. See Berlin & Meinecke, supra note 26, at 601-02; see also AMERICAN
PSYCHIATRIC ASSOCIATION, DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL
DISORDERS 525 (4th ed. 1994) (hereinafter DSM-IV); Vernon L. Quinsey & W. L.
Marshall, Procedures for Reducing Inappropriate Sexual Arousal: An Evaluation
Review, in THE SEXUAL AGGRESSOR 267 (Joanne G. Greer & Irving Stuart eds.,
1983).
29. See Berlin & Meinecke, supra note 26, at 602.
30. See id
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voices commanding particular behavior.3' An adolescent may use a
32smaller child to learn about sex. Any of these individuals could com-
mit the same criminal offense; each of these individuals would be diag-
nosed and treated differently in the medical community. 33 None of these
offenders would be considered pedophiles in the psychiatric
profession.
34
The medical research on the efficacy of MPA in the treatment of sex
offenders has focused on the treatment of paraphilias. 35 Paraphilia,
which includes pedophilia, is a category of mental disorder character-
ized by recurring, detailed sexual fantasies about deviant sex, sexual
behavior enacting the deviant fantasies, and a compelling emotional
desire to enact the fantasies.36 Thus, the disorder is characterized by
cognitive, behavioral, and emotional elements.37 Although there is some
dispute in the psychiatric community regarding the classification of
certain sexual deviances as mental disorders, 3 the profession's diagnos-
tic text, the Diagnostic and Statistical Manual of Mental Disorders
(DSM-IV) includes paraphilias in its catalog of mental disorders.39
31. See id
32. See Abel & Rouleau, supra note 25, at 140.
33. See Berlin & Meinecke, supra note 26, at 602. See also DSM-IV, supra
note 28, at 525. Frequently, a complete diagnosis indicates that a person with one
paraphilic disorder also has another, or the paraphilia is present in combination
with other non-sexual disorders. See id.
34. See Berlin & Meinecke, supra note 26, at 602.
35. See id. at 602-05.
36. Seeid at60l.
37. See DSM-IV, supra note 28, at 528. A diagnosis of pedophilia is appropri-
ate when the following elements are present:
1) Over a period of at least six months recurrent, intense sexually
arousing fantasies, sexual urges, or behaviors involving sexual ac-
tivity with a prepubescent child or children (generally age 13 years
or younger).
2) The fantasies sexual urges, or behaviors cause clinically signifi-
cant distress or impairment in social, occupational, or other impor-
tant areas of functioning.
3) The person is at least age 16 years and at least 5 years older than
the child or children in criterion A.
DSM-IV § 302.2.
38. See Kansas v. Hendricks, 117 S. Ct. 2072, 2081 n.3 (1997) (citing the op-
posing views of two amici, the American Psychiatric Association and the Men-
ninger Foundation, regarding whether sexual deviances should be considered men-
tal disorders).
39. See DSM-IV, supra note 28, at 524.
1999]
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Pedophilia, as well as the other paraphilic disorders, 40 is. believed to
begin in childhood or adolescence and tends to be a lifelong, chronic
disorder.4' There are two types of pedophiles, those who are sexually
attracted only to children (exclusive type) and those who are sexually
attracted to both adults and children (nonexclusive type).
42
B. MPA Treatment
Section 645 of the California Penal Code specifies the use of MPA or
its chemical equivalent to treat certain sex offenders. 43 MPA is com-
monly referred to by its trade name Depo-Provera, a product of the Up-
john Company (now called Pharmacia-Upjohn). 44 It is a synthetic form
of the hormone progesterone that is prescribed primarily as a female
contraceptive.45 Since the late 1960s, MPA has also been the subject of
research in the treatment of men who suffer from certain sexual disor-
ders, most frequently from one or more paraphilias.46
40. Other paraphilias include exhibitionism, fetishism, frotteurism, sexual
masochism, sexual sadism, transvestic fetishism, and voyeurism. See id at 523.
The most common paraphilias seen in clinics are pedophilia, voyeurism, and exhi-
bitionism. See id at 524.
41. See id. at 524.
42. See id. at 528.
43. See CAL. PENAL CODE §§ 645(a) & (b) (West Supp. 1997).
44. See PHYSICIAN'S DESK REFERENCE 2259 (Medical Economics Company
ed., 1998) [hereinafter PHYSICIAN'S DESK REFERENCE].
45. MPA, or Depo-Provera, has been labeled for use as a contraceptive since
1992. See Warren E. Leary, U.S. Approves Injectable Drug as Birth Control, N.Y.
TIMES, Oct. 30, 1992, at Al. See also PHYSICIAN'S DESK REFERENCE, supra note
44, at 2259. Previously, it was not used in the United States as a contraceptive
because of animal studies which indicated an increased risk of certain cancers fol-
lowing long-term use. See Leary, supra.
46. See Money, supra note 18, at 165. MPA has not been labeled by the Food
and Drug Administration for use as a treatment for paraphilias. See J. Kenneth
Fuller, Child Molestation and Pedophilia: An Overview for the Physicians, 261
JAMA 602, 604 (1989). However, physician's may prescribe medication for an
unlabeled use if "they share the basis for their recommendation with and gain the
informed consent from the patient." Id See also infra note 157. Other therapies
used to treat paraphilias are behavior therapy, aversion therapy, and psychotherapy.
See Grossman, supra note 1, at 424, 429-435; see also Gene G. Abel & Candice A.
Osborn, Pedophilia, in TREATMENTS OF PSYCHIATRIC DISORDERS 1959, 1962-1973
(Glen 0. Gabbard ed., 1995) (reviewing a variety of behavioral and cognitive
therapies).
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MPA, and other antiandrogens, 47 may be effective in treating men
with a paraphilic disorder because of its physiological effect in de-
creasing the body's level of testosterone. 48 The decreased production of
testosterone lowers the man's sex drive, and has a corresponding effect
on the frequency of sexual fantasies. 49 This effect is reversible within
several months from the time the treatment is discontinued.50
C. MPA Treatment Studies
A number of studies demonstrate that MPA can be an effective treat-
ment for pedophiles and other paraphilics.5 ' Although the studies gener-
ally include individuals who have previously been arrested or convicted
of a sexual offense, there is no research data on the use of MPA treat-
ment on involuntary subjects.52
47. Antiandrogens are hormones or synthetic hormones that reduce the body's
level of serum testosterone. See Grossman, supra note 1, at 426. In the United
States, MPA has been studied and used to treat sexual disorders. See id. In Europe
and Canada, cyproterone acetate (CPA), another antiandrogen, is used. See id
CPA is not available in the United States because it has not been approved by the
Food and Drug Administration. See Fred S. Berlin, Special Considerations of the
Psychiatric Evaluation of Sex Offenders against Minors, in JUVENILE PSYCHIATRY
AND THE LAW 119, 127 (Richard Rosner & Harold I. Schwartz eds., 1989).
48. See Berlin, supra note 47, at 127. For a more comprehensive discussion of
the science of hormonal activity and MPA, see John M. W. Bradford, Organic
Treatments for the Male Sexual Offender, 3 BEHAV. SCI. & L. 355 (1985).
49. See Oscar A. Cordoba & James L. Chapel, Medroxyprogesterone Treat-
ment of Hypersexuality in a Pedophiliac Sex Offender, 140 AM. J. PSYCHIATRY
1036, 1037 (1983).
50. See Berlin & Meinecke, supra note 26, at 603.
51. See id.; Cordoba & Chapel, supra note 49, at 1036-37; Pierre Gagne,
Treatment of Sex Offenders with Medroxyprogesterone Acetate, 138 AM. J.
PSYCHIATRY 644, 644 (1981); Money, supra note 18, at 165; John Money & Rich-
ard G. Bennett, Postadolescent Paraphilic Sex Offenders: Antiandrogenic and
Counseling Therapy Follow-up, 10 INT. J. MENTAL HEALTH 122, 122 (1981).
52. See Carol Bohmer, Legal and Ethical Issues in Mandating Treatment: The
Patient's Rights v. Society's Rights, in THE SEXUAL AGGRESSOR 11 (Joanne G.
Greer & Irving R. Stuart eds., 1983).
One MPA treatment program that is not mentioned in the legislative history of
Section 645 is the state's own work at Atascadero State Hospital. The California
Departments of Corrections and Mental Health, in conjunction with the National
Institute of Mental Health, conducted a ten year counseling program for sex of-
fenders at Atascadero. See Seligman, supra note 5, at C I. The program sent vol-
unteer prisoners serving the last two years of their sentence to the state hospital for
1999]
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MPA can be administered either as an injection or in pill form. How-
ever, it is usually injected because treatment compliance is easier to
monitor." MPA treatment requires regular injections and blood moni-
toring of testosterone levels, usually on a weekly or biweekly basis.
54
The dosage may be adjusted on an individual basis to ensure that sexual
function is retained. 55 Dr. Fred Berlin, of Johns Hopkins University, one
of the leading experts on the treatment of sexual disorders, has described
MPA treatment as "a sexual appetite suppressant." 56 The effects of the
treatment allow the patient relief from the demands and insistence of his
sexual drive,57 thereby helping him to conform his behavior to societal
norms.
58
The Johns Hopkins University's National Institute for the Study, Pre-
vention and Treatment of Sexual Trauma has been studying MPA and
using it to treat certain sexual disorders since 1966.f In one study of
twenty paraphilics, only three of twenty men had reoccurrences of devi-
ant sexual behavior while on the medication, an eighty-five percent suc-
cess rate.60 Ten out of eleven men who discontinued MPA treatment
against medical advice relapsed into deviant behavior.6' The patients
therapy. See id. Mark Daigle, the director of forensic psychiatric services at the
hospital, reported that about 20 prisoners volunteered for the MPA treatment and
experienced decreased sex drive under the drug's effects. See Lesher, supra note 4,
at A3. However, the hospital did not track the prisoners, now released, to deter-
mine the long-range effectiveness of the treatment. See id. In 1993, the prisoners
who were selected for the Atascadero program had an 11% recidivism rate, while
the control group who declined treatment and remained in prison had a 15% recidi-
vism rate. See Seligman, supra note 5, at C1. Regarding the new statute, Dr. Dai-
gle said that "it would be difficult to tell how successful a mandatory program
might be." Lesher, supra note 4, at A3.
53. See Berlin & Meinecke, supra note 26, at 603.
54. See Berlin, supra note 47, at 127.
55. See id,
56. Fred S. Berlin, The Paraphilias and Depo-Provera: Some Medical, Ethical
and Legal Considerations, 17 BULL. AM. ACAD. PSYCHIATRY & L. 233, 235
(1989).
57. See id; see also Fitzgerald, supra note 24, at 7.
58. See Fitzgerald, supra note 24, at 6-7; Fred S. Berlin, Sex Offenders: A Bio-
medical Perspective and a Status Report on Biomedical Treatment, in THE SEXUAL
AGGRESSOR 103 (J. Greer and I. Stuart eds., 1983).
59. See Fitzgerald, supra note 24, at 8; see also Berlin & Meinecke, supra note
26, at 603; Money, supra note 18, at 165;
60. See Berlin & Meineke, supra note 26, at 604.
61. See id at 605.
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underwent extensive psychiatric screening before treatment to ensure a
complete psychiatric diagnosis and were monitored throughout the du-
ration of the treatment.62 The treatment was not effective on patients
who, in addition to being diagnosed with paraphilia, also have an antiso-
cial personality.63 In addition, patients who had alcohol or substance
abuse problems had less success. 64 After treatment was discontinued, the
relapse rate increased dramatically. 65 These results are similar to those
of other researchers.66
An important component of MPA treatment studies is some form of
talk therapy. 67 MPA does not alter the nature of the patient's sexual de-
68sires. Therefore, in order to prevent relapse, the patient must have an
understanding of the stressors which trigger his deviant behavior. 69 Ide-
ally, the patient gains or improves his ability to reorient his sexual desire
to acceptable forms.7°
The possible medical effects of long-term MPA usage are unknown.
7 1
Short-term side effects include weight gain, mild lethargy, cold sweats,
62. See Fitzgerald, supra note 24, at 5-6 n.23.
63. See Gagne, supra note 51, at 645.
64. See Berlin & Meinecke, supra note 26, at 605.
65. See id.
66. See Cordoba & Chapel, supra note 49, at 1037 (reviewing similar results of
other studies); Gagne, supra note 51, at 645-46 (reporting that forty of forty-eight
patients refrained from committing any offenses during MPA and counseling
treatment; seven patients who were also diagnosed with antisocial personality
"showed no change in sexual behavior."). The Rosenberg Clinic of Galveston,
Texas, conducted a study with 40 men who were treated with Depo-Provera and
counseling. See Seligman, supra note 5, at Cl. Eighteen percent committed new
crimes during treatment and an additional thirty-five percent committed new of-
fenses after the MPA treatment ended. See id.; see also, supra note 52 (describing
California's Atascadero study).
67. See Berlin & Meinecke, supra note 26, at 603. Specialists are opposed to
the use of MPA without some form of therapy. See Seligman, supra note 5, at Cl
(quoting Robert Freeman-Longo, director of the Safer Society Foundation, "you
just don't use this drug in the absence of therapy.").
68. See Berlin & Meinecke, supra note 26, at 606.
69. See id. at 603; see also Seligman, supra note 5, at CI ("Therapy that works
involves group or individual sessions in which offenders learn to recognize the
internal triggers that cause their behavior. Those can be loneliness, boredom, de-
pression or external triggers like drugs, alcohol, or being around schools or play-
grounds.").
70. See Berlin & Meinecke, supra note 26, at 603.
7 1. See Fitzgerald, supra note 24, at 7.
722 Journal of Contemporary Health Law and Policy [Vol. 15:711
hot flashes, nightmares, hypertension, elevated blood sugar, shortness of
breath, and lessened testis size.7
MPA treatment studies have been constrained by certain methodo-
logical limitations.73 One clear limitation on deriving accurate data is
that relapse is largely measured by the patient's self-report.74 The pa-
tient's family members and the police or probation officers also serve as
additional sources of relapse information. 75 All three sources, however,
are inherently unreliable indicators. The patient, at risk for arrest, is not
motivated to discuss his relapse, while family members and police may
not have full knowledge of the patient's behavior.76 Success rates are
therefore likely to be overstated.77 Research critics also note that MPA
studies are not amenable to normal clinical testing procedures, such as
double-blind testing.78 Because paraphilic behavior endangers the pub-
lic, researchers cannot ethically utilize placebos to test the drug's effec-
tiveness.79 Finally, there has been no study of sufficient duration to de-
termine the effects that long-term MPA usage may have on the male
body. s°
II. PRIOR USE OF MPA TREATMENT IN THE
CRIMINAL JUSTICE SYSTEM
Legislation requiring or permitting the use of MPA treatment is a new
development in the law. The treatment has, however, been used within
the criminal justice system on a voluntary basis, often as a condition of
parole.8 ' In addition, several states, including Minnesota, Connecticut
and Oregon, have studied the treatment for possible use in the criminal
72. See Icenogle, supra note 24, at 285 (1994) (citing Lehne, Treatment of Sex
Offenders with Medroxyprogesterone Acetate, in 6 HANDBOOK OF SEXOLOGY: THE
PHARMACOLOGY AND ENDOCRINOLOGY OF SEXUAL FUNCTION 516, 522 n. 46
(1988)).





78. See Grossman, supra note 1, at 426.
79. See id
80. See id. at 436.
81. See John T. Melella et al., Legal and Ethical Issues in the Use of Antian-




California has also studied MPA treatment for sex offenders. At Atas-
cadero State Hospital, the Departments of Corrections and Mental
Health conducted a ten year study of treatment programs for sex offend-
ers, including twenty offenders who volunteered for MPA treatment. 3
However, the hospital has not tracked the prisoners, now released, to
determine the long-range effectiveness 
of the treatment.
8 4
In the reported case law, MPA treatment has arisen in two contexts. In
Michigan v. Gauntlet, 5 the Michigan Court of Appeals considered
whether MPA treatment may be used as a judicially-imposed condition
of probation. 6 In Arizona v. Christopher,7 the Arizona Supreme Court
considered whether MPA might be a constitutionally required rehabili-
tative treatment for a paroled sex offender.
88
In Gauntlet, the defendant, who was convicted of offenses arising
from sexual intercourse with his fourteen year old stepdaughter, ap-
pealed the trial judge's sentence which conditioned probation on the
requirement that the defendant undergo MPA treatment.8 9 Although the
defendant argued that the probation condition was unconstitutional, the
Court of Appeals did not address the constitutional issues.90 The court
held that the probation condition was unlawful because, in the absence
of a specific statutory provision, it was beyond the judge's authority to
sentence a person to an "experimental treatment." 91 The court deter-
mined that MPA treatment for sexual deviants had not gained accep-
tance in the medical community as a safe and reliable medical proce-
dure.92 It also examined some of the clinical research, noting that in each
instance MPA treatment was voluntary and accompanied by psychother-
82. See Anthony Schmitz, A Shot in the Dark, HEALTH, Jan. 1993, at 22-24.
83. See Seligman, supra note 5, at C1; see also Lesher, supra note 4, at A3.
84. See Lesher, supra note 4, at A3.
85. 352 N.W.2d 310, 314 (Mich. Ct. App. 1984),modified, 352 N.W.2d 463
(Mich. 1984).
86. Seeid. at314.
87. 652 P.2d 1031 (Ariz. 1982).
88. See id.
89. See Gauntlet, 352 N.W.2d at 314.
90. See id.
91. Seeid. at315-16.
92. See id. at 316. The court examined a report of the Connecticut Department
of Corrections, Report of the Depo-Provera Study Group (Oct. 4, 1983), which
found that the drug had significant safety concerns. See id. at 315.
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apy.93 The court was also concerned that the treatment was not available
in any Michigan facility.
94
In Christopher, the Arizona Supreme Court discussed MPA treatment
in the context of a defendant's constitutional argument that he had a
right to treatment for his sexual disorder. 95 The defendant, a convicted
sex offender, committed new offenses while on probation.96 His proba-
tion was revoked, and he was convicted for the new offenses. 97 On ap-
peal, the defendant argued that the state acquired a constitutional obli-
gation to provide treatment when it placed him on probation, since his
subsequent offenses subjected him to lengthy prison sentences.98 He
identified chemical castration and behavior modification therapy as the
treatments the state was required to provide, based on the pre-sentence
report of a psychiatrist in the first conviction.99 The psychiatrist's report
characterized chemical castration as a "drastic treatment."' 00 The court
found no persuasive legal basis for a due process right to rehabilitation,
and did not directly address the propriety of MPA treatment.' 0'
III. PROVISIONS OF THE STATUTE AND LEGISLATIVE HISTORY
A. Provisions of the Statute
Section 645102 requires a mandatory sentence of MPA treatment upon
93. See id.
94. See id. at 316. The Court referred to the "virtual impossibility of perform-
ance," questioning where the defendant would get the treatment and who would
administer it. See id.
95. Christopher, 652 P.2d at 1032.
96. See id. at 1032.
97. See id.
98. See id. at 1032-33.
99. See id at 1032.
100. See Christopher, 652 P.2d at 1032. The psychiatrist also reported that
Christopher was a poor candidate for treatment because he was not motivated to
change and did not show remorse for his conduct. See id
101. See id at 1034.
102. In the same legislation the prior § 645 was repealed. 1996 Cal. Stats. 596 §
1 (A.B. 3339). The prior § 645 authorized courts to order an operation for the pre-
vention of procreation upon the conviction of a male or female of a sexual offense
against a child under the age often. See CAL. PENAL CODE § 645 (1988). In one
reported case, the court affirmed the sterilization of a man convicted of raping a
thirteen year old girl and possibly infecting her with syphilis. See People v. Blank-
enship, 61 P.2d 352 (Cal. Ct. App. 1936).
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parole for a second conviction for enumerated sex offenses where the
victim is under thirteen years old. 0 3 It also provides for discretionary
sentencing to the chemical treatment upon parole of first time
offenders.' 4 The statute took effect for convictions occurring after Janu-
ary 1, 1997.'05 It applies to the following offenses: forcible sodomy,'
°6
aiding and abetting forcible sodomy, 10 7 a forcible lewd or lascivious
act,108 oral copulation,1°9 forcible oral copulation, or aiding and abetting
The text of the statute is:
Section 645: Medroxyprogesterone acetate treatment for parolees
who have committed specified sex offenses.
(a) Any person guilty of a first conviction of any offense specified
in subdivision (c), where the victim has not attained 13 years of age,
may, upon parole, undergo medroxyprogesterone acetate treatment
or its chemical equivalent, in addition to any other punishment pre-
scribed for that offense or any other provision of law, at the discre-
tion of the court.
b) Any person guilty of a second conviction of any offense speci-
ied in subdivision (c), where the victim has not attained 13 years of
age, shall, upon parole, undergo medroxyprogesterone acetate treat-
ment or its chemical equivalent, in addition to any other punishment
prescribed for that offense or any other provision of law.
(c) This section shall apply to the following offenses:
1 Subdivision (c) or (d) of Section 286.
2 Paragraph (1) of subdivision (b) of Section 288.
3) Subdivision (b) or (d) of Section 288a.
4 Subdivision (a) or (0) of Section 289.
(d)The parolee shall begin medroxyprogesterone acetate treatment
one week prior to his or her release from confinement in the state
prison or other institution and shall continue treatments until the
Department of Corrections demonstrates to the Board of Prison
Terms that this treatment is no longer necessary.
(f) The Department of Corrections shall administer this section and
implement the protocols required by this section. Nothing in the
protocols shall require an employee of the Department of Correc-
tions who is a physician and surgeon ... to participate against his or
her will in the administration of the provisions of this section.
These protocols shall include, but not belimited to, a requirement to
inform the person about the effects of hormonal chemical treatment
and any side effects that may result from it. Aperson subject to this
section shall acknowledge the receipt of this information.
CAL. PENAL CODE § 645(a) (West Supp. 1997).
103. See CAL. PENAL CODE § 645.
104. See id. § 645(a).
105. See Victoria Slind-Flor, Permanent Cuffs for Molesters?, NAT. L. J., Jan.
27, 1997, at A6.
106. See CAL. PENAL CODE § 286(c) (West Supp. 1997).
107. See id § 286(d).
108. See id. § 288(b)(1).
109. See id. § 288a(b).
1999]
726 Journal of Contemporary Health Law and Policy [Vol. 15:711
forcible oral copulation of a person,"10 and forcible penetration with a
foreign object."'
Under the statute, the treatment begins one week prior to the pris-
oner's release on parole, and continues "until the Department of Correc-
tions demonstrates to the Board of Prison Terms that... [it] is no longer
necessary."' 12 The only way a parolee can avoid chemical castration is to
undergo surgical castration." 3 The Department must inform the prisoner
both about the effects of MPA treatment and its side effects." 
4
B. Legislative History
Section 645 was introduced on April 17, 1996 in Assembly Bill 3339
by Assembly Member Bill Hoge. 1 5 Originally, the proposed statute be-
gan, "[A]ny person guilty of a third conviction of any of the following
offenses shall be punished by chemical castration.''l1 6 Assemblyman
Hoge stated that the purpose of the bill was to prevent or lessen recidi-
vism, noting that in the United States "about half of all [sex] offenders
are rearrested."
'1 17
The bill was sponsored by a Pasadena-based organization called the
Women's Coalition, which has been active in promoting legislative
110. See id. § 288a(d).
11. See CAL. PENAL CODE § 289(a), § 289(j).
112. Id. § 645(d).
113. See id § 645(e).
114. See id § 645(f).
115. The provisions of the original bill were:
Section 1. Section 667.73 is added to the Penal Code, to read:
(a) Any person guilty of a third conviction of any of the following
offenses shall be punished by chemical castration, in addition to any
other punishment prescribed by those provisions or any other provi-
sion of law:
S1)Subdivision (c) of Section 286.
2) Subdivision (b) or (c) of Section 288a.
3) Subdivision (j) of Section 289.
b) The person s all be chemically castrated one week prior to his or
her release from confinement in the state prison or other institution
and shall continue chemical castration treatments until a panel of
experts deems it no longer necessary.
(c) The person may choose permanent, surgical castration in lieu of
chemical castration pursuant to this section.
A.B. 3339 (Cal. Apr. 17, 1996).
116. Id (emphasis added). A legislative history of the bill can be found by vis-
iting <http://www.leginfo.ca.gov>.
117. Report of the Assembly Committee on Public Safety, A.B. 3339 (Apr. 22,
1996), at 5 [hereinafter Public Safety Report].
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measures to protect children from molesters.' 18 The Women's Coalition
was founded by Susan Carpenter-McMillan, a former media representa-
tive and activist for the Right to Life League of Southern California,''
9
and consists solely of a six-member board. 120 The organization is funded
by Carpenter-McMillan's husband, William'McMillan, a personal injury
attorney, with an estimated 1997 budget of $15 ,00 0 .i
21
The Women's Coalition proposed the measure following the release
of Richard Muldrew, dubbed the "Pillowcase Rapist," from a California
prison in December 1995.122 The Coalition developed the "chemical
castration" proposal in response to the request of Muldrew's victims.
23
Carpenter-McMillan told the press that when "[w]e ... asked what [the
victims] wanted done ... they all said that they wanted castration." 24
One of the victims later testified at the hearing of the Senate Committee
on Criminal Procedure.'
25
In the California Assembly, the bill was assigned to the Committee on
Public Safety and the Appropriations Committee. 126 The Public Safety
Committee recommended amendments to change the terms of subsection
(b) so that the mandatory provision would apply after a second convic-
tion rather than after a third conviction. 27 The Committee observed that
few offenders would be subject to the statute on a third conviction since
current sentencing requirements would keep the offenders in prison
118. See Welcome to the Women's Coalition (visited Jan. 4, 1999)
<http://www.womenscoalition.org/>.
119. See Lloyd Grove, Cause Celebre, WASH. POST, Jul. 23, 1997, at Cl. Car-
penter-McMillan has also received national media attention in the past year be-
cause of her role as friend and sometime spokesperson for Paula Jones in
Ms. Jones' lawsuit against the President. See id. See also Carla Hall, Force of
Nature, L.A. TIMES MAGAZINE, Dec. 14, 1997, at 26.
120. See Hall, supra note 119, at 26.
121. See Grove, supra note 119, at C1.
122. See Vincent J. Schodolski, California OKs 'Castration' Bill, CHI. TRIB.,
Aug. 31, 1996, at Al.
123. See id.
124. Id.
125. See Nancy HilI-Holtzman, State Panel OKs Chemical Castration Bill, L.A.
TIMES, Jul. 3, 1996, at B4.
126. See A.B. 3339 Complete Bill History (visited Feb. 9, 1999)
<http://www.leginfo.ca.gov/pub/95-96/bill/asm/ab_3301-3350/ab_3339_bill his-
tory.html>.
127. See Public Safety Report, supra note 117, at 5.
19991
Journal of Contemporary Health Law and Policy [Vol. 15:711
without parole for twenty-five years to life. 128 The Committee also noted
that the provisions might violate the California Constitution's prohibi-
tion on cruel and unusual punishment. 129 However, rather than contem-
plating what type of amendments might cure any state constitutional
question, the Committee merely asserted that it is the "domain of the
Legislature to craft laws that punish criminal behavior.
'
30
After passing the Assembly, the bill was sent to the Senate, where it
was heard by the Committee on Criminal Procedure and the Appropria-
tions Committee. The Senate added a provision giving judges the dis-
cretion to apply the statute to first-time offenders.' Another provision
was added to delegate the development of further policy to the Depart-
ment of Corrections. 132 The Senate amended the bill again, adding the
informed "nonconsent" provision, which requires the Department of
Corrections to inform the prisoner of the effects and side effects of
chemical castration, and to acquire from the prisoner an acknowledg-
ment that the information was provided. 3 3 The final amendment was
made on August 20, 1996, when the Senate added the provision that
state-employed doctors would not be forced to participate in the admini-
stration of MPA treatment. 1
34
The bill was supported by references to medical studies, particularly
those of Dr. Fred Berlin of Johns Hopkins University.135 However, the
provisions were not written under the guidance of, or with the contribu-
tion of, medical experts. 1
6
By the time the bill was sent to the Governor, many of its practical,
medical, and legal problems had been noted, without being addressed by
128. See id
129. See id. at 6.
130. Id.
131. See Report of the Senate Committee on Criminal Procedure, A.B. 3339
(June 17, 1996), at 5 [hereinafter Criminal Procedure Report].
132. See Floor Report of the Senate Rules Committee, A.B. 3339 (Jul. 9, 1996),
at 4 [hereinafter July Floor Report].
133. See id.
134. See Floor Report of the Senate Rules Committee, A.B. 3339 (Aug. 20,
1996), at 5 [hereinafter August Floor Report].
135. See, e.g., Criminal Procedure Report, supra note 131, at 6-7.
136. See Shari Roan, No Consensus on Chemical Castration, L.A. TIMES, Sept.
26, 1996, at El. "This law hasn't been done out of a collaboration between medi-
cal and science people and the criminal justice system ... the legislature did not
say ... let's get some experts together and ask them what would make sense."
Id (quoting Dr. Fred Berlin).
Medicine for Molesters
further amendment. Issues raised in the Senate Committee on Criminal
Procedure included the absence of a counseling provision, the ethical
concerns of health professionals in forcing parolees to submit to treat-
ment, the legality under California law of forcing parolees to accept an
unwanted medical treatment, and federal constitutional issues.
31
The Floor Report of the Senate Rules Committee noted that the
"measure poses serious bioethical problems ... [including] whether the
state should 'practice medicine' by . . . mandating weekly injections
regardless of effectiveness, . . . [and] regardless of whether individuals
can tolerate the drug."' 38 The Committee also noted that "[t]his measure
poses serious ... legal problems [and] ... this drug merely functions as
a form of birth control with women.' 39
The California Psychiatric Association (CPA) opposed the bill be-
cause "psychiatrists fundamentally believe that not all offenders would
necessarily benefit from this type of treatment intervention."
' 140
Dr. Berlin, whose research and statements were used by the legisla-
ture to bolster its position on the effectiveness of MPA treatment of sex
offenders,'14 was also quoted on the medical and ethical concerns of the
psychiatric community. 42 He "would be opposed to the imposition of
Depo-Provera treatment upon an unwilling individual... in the absence
of medical testimony that such treatment was appropriate, and in the
absence of prior agreement from the prospective patient that he was in-
terested in receiving it."
1 43
Other parties who opposed the bill were the California Attorneys for
Criminal Justice and the American Civil Liberties Union (ACLU).
44
137. See Criminal Procedure Report, supra note 131.
138. See August Floor Report, supra note 134, at 8.
139. See id
140. See id (quoting an August 2, 1996 letter to Assemblyman Bill Hoge from
the California Psychiatric Association in opposition to A.B. 3339):
141. See, e.g., August Floor Report, supra note 134, at 5-6,
142. See Criminal Procedure Report, supra note 131, at 8 (including Dr. Ber-
lin's remarks critical of the imposition of MPA treatment on convicted sex offend-
ers). The final Senate report, the Floor Report of the Committee on Rules of
August 20, 1996, does not include these remarks and only cites Dr. Berlin's re-
search and statements on success rates of testosterone-reducing therapies and sur-
geries. See August Rules Report, supra note 134.
143. Criminal Procedure Report, supra note 131 (citing Fred S. Berlin, The
Paraphilias and Depo-Provera: Some Medical, Ethical and Legal Considerations,
17 BULL. AM. ACAD. PSYCHIATRY L. 233, 236 (1989)).
144. See August Floor Report, supra note 134, at 7.
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The California Attorneys for Criminal Justice cautioned that forcibly
medicating people violated the Eighth Amendment's prohibition on
cruel and unusual punishment. 45 The ACLU was particularly concerned
that the treatment was not voluntary and that it did not include any
counseling.146 The ACLU noted that none of the law enforcement agen-
cies supported the bill.
47
No organization other than the Women's Coalition supported the
bill. 141
C. Two Years Later: Developments
Since 1996, there have been few developments in the application of
Section 645, precluding any practical determinations about its applica-
tion and effectiveness. The Department of Corrections decided that Sec-
tion 645 applies only to prisoners who were sentenced after the law took
effect on January 1, 1997. . Under current sentencing provisions, which.
impose a minimum of three years for the applicable offenses,150 the stat-
ute will be applied or challenged in the coming years. The Department
of Corrections also decided that the Department itself cannot order MPA
injections without first obtaining a court order.' 51 By late 1998, eleven
cases were referred to the courts and in only one case was the treatment
ordered. 152 In that case, the prisoner will not be eligible for parole until
2002.'
The Board of Prison Terms, the agency responsible for determining
parole conditions generally, as well as deciding when the ordered treat-
ments end, recently promulgated two regulations under Section 645.154
One regulation simply restates the Board's responsibility under Section
145. See Schodolski, supra note 122, at 1.
146. See August Floor Report, supra note 134, at 8-9.
147. See id.
148. See id.
149. See Associated Press, After a Year, Castration Law has been Invoked Just
Once, SAN DIEGO UNION-TRIBUNE, Nov. 26, 1998, at A6 [hereinafter Castration
Law].
150. See August Floor Report, supra note 134, at 4 (summarizing the
sentencing provisions of the applicable offenses).
151. See Castration Law, supra note 149, at A6.
152. See id.
153. See id.
154. See CAL ADMIN. CODE tit. 15, §§ 2513.1-2513.2 (1998).
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645.155 The second establishes a hearing procedure to be used when the
Department of Corrections determines that the treatment is either no
longer necessary, or that the parolee has a medical condition requiring
termination of the treatments. 56 It remains to be seen whether the De-
partment of Corrections will combine Section 645's chemical castration
provision with other types of therapy.
IV. PRESCRIBING MEDICINE BY LEGISLATIVE ENACTMENT
When a state mandates that individuals receive an involuntary medical
treatment, important bioethical and constitutional issues necessarily
arise.'57 Section 645, however, adds yet another difficulty: it erases the
role of the doctor from the treatment.
California has a powerful interest in preventing sexual assault against
children. The statute California enacted to help achieve that goal, how-
ever, pulls a medical treatment into the criminal justice system, 58 with-
out bringing along the doctor.159 Section 645 by its terms prevents indi-
155. See id. § 2513.1.
156. See id § 2513.2. Since the regulation speaks of terminating treatment in
the case of a parolee's medical condition, it appears that the Board does not con-
sider itself to have the discretion to order, prior to the imposition of the treatment,
that no treatments be given to a parolee coming under the statute's mandate. The
regulation does provide that the Board can order suspension of the treatments while
the hearing is pending. See id
157. See, e.g., Melella, supra note 81, at 223.
158. Under California law, individuals, including prisoners, have a fundamental
right to refuse medical treatment, but this right can be outweighed by countervail-
ing state interests, including the protection of third parties. See Thor v. Andrews,
855 P.2d 375, 387 (Cal. 1993) (explaining that the concern for third parties can
arise when the refusal of medical treatment endangers public health).
159. It is possible that § 645 violates the misbranding provisions of the Food,
Drug and Cosmetic Act (FDCA). Depo-Provera has not been labeled for the treat-
ment of sexual disorders. See Max Vanzi, Assembly OKs Castration Drug for
Molesters, L.A. TIMES, Aug. 31, 1996, at Al. The Food and Drug Administration
(FDA) has "previously interpreted FDCA's labeling requirements to impose upon
FDA the 'obligation' to investigate and take appropriate action against unapproved
uses of approved drugs where such unapproved use becomes widespread or endan-
gers the public health." Chaney v. Heckler, 718 F.2d 1174, 1176 (D.C. Cir. 1984)
(quoting Legal Status of Approved Labeling for Prescription Drugs: Prescribing
for Uses Unapproved by the Food and Drug Administration, 37 FED. REG. 16503,
16504 (Aug. 15, 1972)), overruled on other grounds, Heckler v. Chaney, 470 U.S.
821 (1985). Although doctors are permitted to prescribe medications for off-label
uses under the "practice of medicine" exception, see Chaney, 718 F.2d at 1179-80,
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vidualized diagnosis of the offender, 160 fails to provide a standard to
determine the dosage of MPA, and creates the possibility that offenders
might be subjected to a continuing ineffective treatment.' 6' Moreover,
Section 645 applies equally to both male and female offenders, although
each responds very differently to MPA. These legislative choices are
contrary to public policy, to established medical ethics, 162 and to com-
mon sense.
Under the provisions of § 645, the entire class of twice-convicted
child sex offenders will be given MPA treatment without consideration
of whether the treatment is appropriate for any individual offender. In
particular, MPA is unlikely to be effective on a pedophile who is also a
substance abuser, or on an individual with an antisocial personality.
63
This approach will, therefore, subject some offenders to an indefinite
course of medication that may not be effective.' 64
MPA also has significant side effects which may require medical su-
pervision. For example, it can raise blood pressure, requiring some pa-
tients on MPA to receive additional medical treatment for the elevated
blood pressure brought on or made worse by MPA. 165 Without a prior
examination and medical history taken by a doctor, some individuals
with preexisting medical conditions, for whom MPA would be contrain-
a statutory mandate like Section 645 would probably not fall within this exception.
In Chaney, the court held that a state's use of drugs for the purpose of lethal injec-
tion when the drugs were not labeled for that use was not an off-label use permitted
under the practice of medicine exception. See id. Finding that Congress' intention
was to prevent FDA interference with the doctor's treatment of his patient, the
court held the state's off-label use in the capital punishment context was a non-
medical use that was not covered by the exception. See id. An FDA spokewoman
said that it was unclear if state criminal justice officials had the same authority as
physicians to prescribe drugs for unlabelled purposes. See Vanzi, supra.
160. See supra note 102 for the exact language of the statute.
161. See August Floor Report, supra note 134.
162. See Richard Lacayo, Sentences Inscribed on Flesh, TIME, Mar. 23, 1992, at
54, 59. "Physicians have no business acting as agents of the state to punish peo-
ple." Id (quoting Dr. George Annas, professor of health law at Boston University
Medical School).
163. See supra notes 63-64 and accompanying text.
164. See Berlin & Meinecke, supra note 26, at 603.
165. See Seligman, supra note 5, at C-1 ("Parolees who get Depo-Provera will
need medical follow-up . . .. The drug can cause high blood pressure, gallstones,
migraine headaches, complications for diabetics and muscle soreness around the
injection sites.")
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dicated, would be endangered by the treatment.
166
Perhaps the most glaring issue that the legislature failed to correct is
the law's application to women. 167 The statute mandates the treatment
upon a second conviction of offenses for which both male and female
offenders may be convicted. 168 The treatment, however, has not been
used on female sexual disorder patients because MPA is solely a contra-
ceptive when taken by women. 169 Since MPA has no effectiveness as a
preventative measure for female recidivism, the application of the law to
women subjects them to an ineffective medical treatment while control-
ling their fertility.
A significant area of concern for mandatory MPA treatment is the
question of what dosage should be used. Section 645 does not contain a
specific dosage requirement. In MPA treatment, the same dosage affects
different individuals differently. 170 Each patient requires monitoring to
ensure proper dosage.'17 Also, the patient gives self-reports so that the
doctor can determine the frequency and intensity of sexual fantasies.
172
Another important consideration is to what extent the individual can
experience sexual arousal. 173 Psychiatrists attempt to adjust the dosage
to the individual so that the frequency and intensity of sexual fantasies is
reduced to the level at which the individual remains in control of his
conduct without removing all sexual function. 174 However, at high
enough dosages, each male recipient could be rendered impotent
166. See August Floor Report, supra note 134. The absence of medical screen-
ing provisions can also be seen in the fiscal analysis of the bill, which calculates
cost estimates solely on the basis of the price of the weekly dosage of MPA. See
July Floor Report, supra note 132, at 7. MPA costs approximately $40.00 per
injection. See id. The Department of Corrections stated that there were 687 pa-
roled sex offenders who had been convicted twice of the specified offenses at the
time the bill was under consideration in 1996. See id
167. See id.
168. See CAL. PENAL CODE §§ 286(c), 286(d), 288(b)(1), 288a(b), 288a(d),
289(a) (West Supp. 1997).
169. See PHYSICIAN'S DESK REFERENCE, supra note 44, at 2083.
170. See Berlin & Meinecke, supra note 26, at 605. In various studies a weekly
injection of 100 to 800 milligrams of MPA has been used. See Fitzgerald, supra
note 24, at 6 (citations omitted).
171. See Money & Bennett, supra note 51, at 125.
172. See id.
173. See id.
174. See Berlin & Meinecke, supra note 26, at 603.
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throughout the treatment.1
75
Section 645 does not clarify its intent with regard to the desired result.
Since the statute was enacted with the specific purpose of preventing
recidivism, 176 and is not concerned directly with treatment, it is conceiv-
able that the statute would be interpreted as intending to render the sex
offender impotent. The placement of the section in the penal code, as
well as its operation as a component of a criminal sentence, would sup-
port this result.
A third element of concern is that the statute specifies that the treat-
ment is to continue "until the Department of Corrections demonstrates to
the Board of Prison Terms that this treatment is no longer necessary.' 77
Since pedophilia is considered a chronic disorder that has no cure, 17' for
pedophile offenders, MPA treatment may be continued throughout the
duration of parole. 79 For offenders who are not pedophiles, MPA will
be less effective, or perhaps entirely ineffective.' 80 Under the terms of
the statute, however, the Department of Corrections would not have the
discretion to decide that such an offender should not receive MPA
treatment. It would be difficult for the Department of Corrections to
establish that the treatment is no longer necessary when it cannot make
assurances about future behavior. Since there is no data on the long-term
effects of MPA on the male body, it is unknown whether indefinite use
of MPA is harmful.' 8'
California has a comprehensive statutory structure to regulate the
practice of medicine for the protection of the public. 82 The Medical
Practice Act makes it unlawful to practice medicine without a license.
8 3
Furthermore, it is a felony if such unlawful practice puts any individual
in serious risk of danger. 8 4 It is clear from the provisions of the Medical
Practice Act that the state considers the practice of medicine to be pro-
fessional activity requiring a high degree of regulation to protect the
175. See id
176. See Preamble, A.B. 3339, 1996 Reg. Sess. (Cal. 1996).
177. CAL. PENAL CODE § 645(d) (West Supp. 1997).
178. See DSM-IV, supra note 28, at 528.
179. See August Floor Report, supra note 134, at 7-8.
180. See Berlin & Meinecke, supra note 26, at 603.
181. See Grossman, supra note 1, at 436.
182. See Medical Practice Act, CAL. Bus. & PROF. CODE § 2000 (West 1988).
183. See id. § 2053.
184. See id.
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health of the public.'8 5 The Act also prohibits the prescription of medi-
cine without a prior examination. 8 6 This provision is consonant with the
American Medical Association's Code of Ethics.18 7 The central element
of medical practice is the doctor-patient relationship, in which treatment
is recommended on an individual basis.1
88
The American Medical Association (AMA) opposes the use of medi-
cal treatment as a part of criminal penalties. 8 9 In the context of surgical
castration, the AMA's Ethics and Health Policy Council has said that,
even if the prisoner gives consent to the procedure, "anything settled in
a courtroom cannot be considered voluntary."' 90 Another medical ethi-
cist stated that "no medical procedure should be done without an indica-
tion and the chance of success."191 Additionally, several victims' thera-
pists have expressed the concern that chemical and surgical castration
impart a "false sense of security" because so many sex offenses are mo-
tivated by factors that are not responsive to decreased testosterone.
92
Moreover, professionals who work with sex offenders have been critical
of California's statute. In a recent report published by the Department of
Justice, California's chemical castration statute was criticized on ethical
grounds for subjecting individuals to a drug that the Food and Drug
.Administration has not approved for use with child molesters; on practi-
cal grounds, because sex offenders are not likely to comply with an in-
voluntary treatment; and on empirical grounds, because the drug has not
185. See id.
186. See id. § 2242(a) ("Prescribing, dispensing, or furnishing dangerous drugs
as defined in Section 4211 without a good faith prior examination and medical
indication therefor, constitutes unprofessional conduct.").
187. See COUNCIL ON ETHICAL AND JUDICIAL AFFAIRS, AMERICAN MEDICAL
ASSOCIATION, CODE OF MEDICAL ETHICS 116 (1996-1997 ed.).
188. "From ancient times, physicians have recognized that the health and well-
being of patients depends upon a collaborative effort between physician and pa-
tient." Id. at xli. The doctor's relationship to his or her patient is described as a
fiduciary relationship. See id.
189. See Lacayo, supra note 162, at 54. "An ethical doctor would not prescribe
a highly questionable drug with numerous side effects to an involuntary patient."
Mary Lynne Vellinga, Castration Law Under Fire, SACRAMENTO BEE, Feb. 4,
1997, at A l (quoting Barbara Schwartz, head of sex offender treatment programs at
the Massachusetts Department of Corrections).
190. See Jennifer Liebrum, Castration Alternatives Criticized, HOUSTON
CHRONICLE, Feb. 7, 1992, at A-2 1.
191. Id.
192. See id.; see also Seligman, supra note 5, at CI.
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been proven to be effective without other treatment therapies and has
not been proven to work on all types of child molesters.' 93 The Associa-
tion for the Treatment of Sexual Abusers does not support the statute
primarily because of its failure to provide for a thorough diagnostic
evaluation, on-going medical supervision, appropriate monitoring, and a
comprehensive treatment plan. 194 Others have expressed concern that the
law will backfire when parolees who receive the involuntary treatment
become embittered or angry.
195
Furthermore, the provisions of Section 645 may violate existing Cali-
fornia law. Under state constitutional and common law, no competent
person may be subjected to involuntary treatment. 96 This civil right was
expressly extended to include prisoners by statutory provision, although
the statute permits the state to deny a prisoner a civil right in order to
maintain prison security or public safety. 197 To apply Section 645, Cali-
fornia must establish that the statute serves to protect public safety. Be-
cause there is no medical evidence that MPA treatment will be effective
on an involuntary patient, g9 and because there is medical evidence that
it will not be effective for all categories of sex offenders 99 or women, 200
it would be hard for the state to establish in particular cases that the
public safety assured by the statute outweighs the violation of the pa-
rolee's civil rights.
Dr. Berlin indicated that he believes there is a role for MPA treatment
within the criminal justice system.2 0' He referred to compulsory vacci-
193. See Robert A. Prentky et al., Child Sexual Molestation: Research Issues
15-16 (National Institute of Justice, 1997) (visited Jan. 12, 1999)
<http://www.ncjrs.org/resdocs.htm>.
194. See Association for the Treatment of Sexual Abusers, Anti-Androgen Ther-
apy and Surgical Castration Policy, (adopted Feb. 7, 1997) (last updated Mar. 11,
1998.) <http://www.atsa.com/pages/policy/anti.html>.
195. See Chemical Castration'Law May Backfire, ACLU NEWSWIRE, Sept. 18,
1996 (quoting Dr. Berlin) (visited Jan. 4, 1999) <http://www.aclu.org/
news/w09l89a.html>).
196. See Keyhea v. Rushen, 223 CAL. RPTR. 746 (App. 1 Dist. 1986); Foy v.
Greenblott, 190 CAL. RPTR. 84 (1983); Cobbs v. Grant, 502 P.2d 1 (1972). Keyhea
was also cited in the Senate Committee on Criminal Procedure Report of July 9,
1996, among others.
197. See CAL. PENAL CODE § 2600 (West 1982 & Supp. 1999).
198. See supra note 52 and accompanying text.
199. See supra Part I(C) at 8.
200. See supra Part IV at 20.
201. See Berlin, supra note 56, at 238.
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nations20 2 as precedent for the notion that medical treatment can be
mandated when there is a clear risk to the well-being of others.0 3 How-
ever, he is
opposed to the imposition of Depo-Provera treatment upon an
unwilling individual, as occurred in the ... Gauntlet case, in the
absence of medical testimony that such treatment was appropri-
ate, and in the absence of prior agreement from the prospective
patient that he was interested in receiving it . . .. In the future if
it were to become clear that given individuals could live safely
within the community while taking Depo-Provera but could not
in its absence, then society might well determine that such per-
sons need either to take it or be quarantined .... The author does
not believe that the evidence of guaranteed increased safety to
the community . . . is at this point in time sufficiently compel-
ling to justify mandating it as treatment in the case of an un-
willing individual.2 °4
V. CONCLUSION
Section 645 sailed through the Legislature without careful considera-
tion of the proper use of MPA treatment. Its application will no doubt be
fraught with the issues addressed in this Comment, such as ineffective-
ness, uncertain duration of treatment, and lack of appropriate medical
supervision. Had the medical community been consulted during the
crafting of this statute, many of these questions could have been ad-
dressed.
The prevention of sexual offenses against children is of vital impor-
tance, and should involve both the criminal justice system and the medi-
cal profession. MPA treatment has the potential to play a valuable role
in the prevention of recidivism of pedophiles. Its potential, however,
should be developed by medical experts. In removing the doctor from
the treatment, Section 645 serves as another punitive tool rather than
serving its intended use as a medical treatment.
Audrey Moog
202. See id at 236. Dr. Berlin is referring to the compulsory vaccinations up-
held in Jacobson v. Massachusetts, 197 U.S. 11, 25-26 (1905) (state's police power
is sufficient to justify compulsory vaccinations where the purpose is to ensure pub-
lic safety).
203. See id.
204. Id.
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